A Study YL201 in Patients With Selected Advanced Solid Tumors
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: YL201 for Injection
- Registration Number
- NCT06057922
- Lead Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
- Brief Summary
This is A Multicenter, Open-Label, Phase 1/2 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients with Selected Advanced Solid Tumors. The study will include 2 parts: Phase 1 dose expansion stage (Part 1) followed by a Phase 2 stage with expanded sample size (Part 2).
Part 1 will estimate the RP2D in dose expansion cohorts of patients with not linited to non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), nasopharyngeal carcinoma (NPC), esophageal squamous cell carcinoma (ESCC), metastatic castration-resistant prostate cancer (mCRPC), etc..
Part 2 will include patients with selected advanced solid tumor types enrolled at the RP2D to further assess the efficacy and safety of YL201.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 640
- Informed of the trial before the start of the trial and voluntarily sign their name and date on the ICF.
- Age ≥18 years old and ≤75 years old
- Histologically or cytologically confirmed at diagnosis of NSCLC/SCLC/NPC/ESCC /mCRPC
- At least one extracranial measurable lesion according to RECIST 1.1.
- Archived or fresh tumor tissue samples can be provided.
- Eastern Cooperative Oncology Group - performance scale (ECOG PS) score of 0 or 1.
- Female subjects with fertility must agree to take high-efficiency contraceptive measures from screening to whole study period and within at least 6 months after last administration of investigational drug. Male subjects must agree to take high-efficiency contraceptive measures from screening to whole study period and within at least 6 months after last administration of investigational drug.
- Life expectancy ≥3 months.
- Capable or willing to observe the visits and procedures stipulated in study protocol.
- Prior treatment with products targeting B7H3 (including antibodies, antibody-drug conjugate [ADC], chimeric antigen receptor T cells [CAR-T], and other drugs).
- Prior treatment with topoisomerase 1 inhibitors or ADC based on topoisomerase 1 inhibitors.
- Participation in another clinical trial meanwhile, except observatory (non-interventional) clinical trial or at follow-up period of interventional study.
- Washout period of previous anticancer treatment was insufficient before first administration of investigational drug.
- Major surgery (excluding diagnostic surgery) within 4 weeks before first administration of investigational drug or likely to require major surgery during the study.
- History of allogenic bone marrow transplantation or solid organ transplantation.
- Treatment with systemic steroid (Prednisone >10 mg/d or equivalent drugs) or other immunosuppressive drugs within 2 weeks before first administration of investigational drug.
- Live vaccination within 4 weeks before first administration of investigational drug or likely to require live vaccine inoculation during the study.
- Evidence of leptomeningeal metastasis or carcinomatous meningitis.
- Evidence of brain metastasis or spinal cord compression.
- Evidence of cardiovascular disease with uncontrolled state or clinical significance.
- Clinically significant concomitant lung disease.
- Diagnosed as Gilbert syndrome.
- Complicated with uncontrolled third-space effusion .
- History of gastrointestinal perforation and/or fistula within 6 months before first administration.
- History of serious infection (Grade ≥3 of NCI CTCAE) before first administration.
- Known as infection with human immunodeficiency virus (HIV).
- Active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).
- History of any other primary malignant tumor within 5 years before first administration of investigational drug.
- The toxicity of previous anticancer treatment is not resolved.
- History of serious hypersensitive reactions to drug substance, inactive compositions of preparations or other monoclonal antibodies.
- Breastfeeding women. Or women confirmed as pregnant through pregnancy test within 3 days before first administration.
- Any disease, medical state, organ/system dysfunction or social state considered by investigators as possibly interfering the subject's capability for ICF signing, producing adverse influence on the subject's capability for cooperation and study participation or influencing the interpretation of study results. Including but not limited to mental disease or substance/alcohol abuse.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Phase 2 stage with expanded sample size YL201 for Injection Patients will be treated with YL201 intravenous (IV) infusion at PR2D once every 3 weeks (Q3W) as a cycle. Phase 1 dose expansion stage YL201 for Injection Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle.
- Primary Outcome Measures
Name Time Method Evaluate the prostate-specific antigen (PSA) response rate for patients with prostate cancer Time Frame: Approximately within 36 months PSA response rate: defined as the proportion of patients who achieved a ≥50% decrease in PSA from baseline
Evaluate the AEs as characterized by type, frequency, severity, timing, seriousness and relationship to study treatment By the global end of trial date, approximately within 36 months Evaluate the objective response rate (ORR) for patients with solid tumors which assessed using RECIST version 1.1 Time Frame: Approximately within 36 months ORR: defined as the proportion of patients who achieved a best overall response of complete response (CR) or partial response (PR).
- Secondary Outcome Measures
Name Time Method Characterize the PK parameter AUC Approximately within 36 months Characterize the PK parameter Vd Approximately within 36 months Characterize the PK parameter t1/2 Approximately within 36 months Characterize the PK parameter CL Approximately within 36 months Evaluate the time to response (TTR) for patients assessed using RECIST version 1.1 Approximately within 36 months TTR: defined as the time interval from the date of the first dose of study drug to the date of the first documentation of objective response (CR or PR).
Evaluate the overall survival (OS) for patients Approximately within 36 months OS: defined as the time interval from the date of the first dose of study drug to the date of death due to any cause.
Evaluate the duration of response (DoR) for patients assessed using RECIST version 1.1 DoR: defined as the time interval from the date of the first documentation of objective response (CR or PR) to the date of the first documentation of PD. DoR will be assessed for patients with a response (CR or PR) only. Approximately within 36 months
Evaluate the time to PSA progression (TTPP) for patients with prostate cancer Approximately within 36 months Defined as the time from the first investigational drug administration to the first recording of PSA progression.
Characterize the PK parameter Ctrough Approximately within 36 months Assess the incidence of anti-YL201 antibodies Approximately within 36 months Evaluate the progression-free survival (PFS) for patients assessed using RECIST version 1.1 Approximately within 36 months PFS: defined as the time interval from the date of the first dose of study drug to the date of first documentation of PD or death due to any cause, whichever occurs first.
Evaluate the best PSA response for patients with prostate cancer Approximately within 36 months Defined as the maximum percentage of PSA changes at any time during the study.
Evaluate the radiographic progression-free survival (rPFS) for patients with prostate cancer Approximately within 36 months Evaluate the PSA duration of response (PDoR) for patients with prostate cancer Approximately within 36 months Defined as the time from PSA reduction of ≥50% compared with baseline to PSA progression.
Characterize the PK parameter Cmax Approximately within 36 months Evaluate the disease control rate (DCR) for patients assessed using RECIST version 1.1 DCR: defined as the proportion of patients who achieved a best overall response of CR, PR or stable disease (SD). Approximately within 36 months
Trial Locations
- Locations (55)
Jiangmen Central Hospital
🇨🇳Jiangmen, Guangdong, China
Affiliated Hospital of Chengde Medical University
🇨🇳Chengde, Hebei, China
Fujian Cancer Hospital
🇨🇳Fuzhou, Fujian, China
The Frist People's Hospital of Foshan
🇨🇳Foshan, Guangdong, China
The Fifth Affiliated Hospital Sun Yat-Sen University
🇨🇳Zhuhai, Guangdong, China
Affiliated Cancer Hospital of Guangxi Medical University
🇨🇳Nanning, Guangxi, China
Binzhou Medical University Hospital
🇨🇳Binzhou, Shandong, China
West China Hospital of Sichuan University
🇨🇳Huaxi, Sichuan, China
Anhui Provincial Cancer Hospital
🇨🇳Hefei, Anhui, China
The First Affiliated Hospital of Anhui Medical University
🇨🇳Hefei, Anhui, China
The First Affiliated Hospital of USTC
🇨🇳Hefei, Anhui, China
The Second Hospital of Anhui Medical University
🇨🇳Hefei, Anhui, China
Chongqing University Cancer Hospital
🇨🇳Chongqing, Chongqing, China
The First Affiliated Hospital of Xiamen University
🇨🇳Xiamen, Fujian, China
Gansu Provincial Cancer Hospital
🇨🇳Lanzhou, Gansu, China
Sun Yat-sen University Cancer Center
🇨🇳Guangzhou, Guangdong, China
Dongguan People's Hospital
🇨🇳Dongguan, Guangdong, China
Yuebei People's Hospital
🇨🇳Shaoguan, Guangdong, China
The Second Affiliated Hospital of Guilin Medical University
🇨🇳Guilin, Guangxi, China
Liuzhou People's Hospital
🇨🇳Liuzhou, Guangxi, China
Liuzhou Worker's Hospital
🇨🇳Liuzhou, Guangxi, China
The People's Hospital of Guangxi Zhuang Autonomous Region
🇨🇳Nanning, Guangxi, China
The First Affiliated Hospital of Hainan Medical University
🇨🇳Haikou, Hainan, China
Harbin Medical University Cancer Hospital
🇨🇳Haerbin, Heilongjiang, China
The First Affiliated Hospital of Henan University of Science and Technology
🇨🇳Luoyang, Henan, China
The First Affiliated Hospital of Xinxiang Medical University
🇨🇳Xinxiang, Henan, China
Henan Cancer Hospital
🇨🇳Zhengzhou, Henan, China
The First Affiliated Hospital of Zhengzhou University
🇨🇳Zhengzhou, Henan, China
Hunan Cancer Hospital
🇨🇳Changsha, Hunan, China
The Second Xiangya Hospital of Central South University
🇨🇳Changsha, Hunan, China
The First People's Hospital of Changzhou
🇨🇳Changzhou, Jiangsu, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
🇨🇳Wuhan, Hubei, China
The Affiliated Hospital of Nanjing University Medical School
🇨🇳Nanjing, Jiangsu, China
Nantong Tumor Hospital
🇨🇳Nantong, Jiangsu, China
Affiliated Hospital of Jiangnan University
🇨🇳Wuxi, Jiangsu, China
Jiangyin People's Hospital
🇨🇳Wuxi, Jiangsu, China
Xuzhou Central Hospital
🇨🇳Xuzhou, Jiangsu, China
First Affiliated Hospital of Gannan Medical University
🇨🇳Ganzhou, Jiangxi, China
Jiangxi Cancer Hospital (Jiangxi Second People's Hospital)
🇨🇳Nanchang, Jiangxi, China
Liaoning Cancer Hospital and Institute
🇨🇳Shenyang, Liaoning, China
The First Affiliated Hospital of Nanchang University
🇨🇳Nanchang, Jiangxi, China
The First Hospital of Jilin University
🇨🇳Changchun, Jilin, China
Shandong Cancer Hospital and Institute
🇨🇳Jinan, Shandong, China
The Frist Hospital of China Medical University
🇨🇳Shenyang, Liaoning, China
Shandong Provincial Hospital
🇨🇳Jinan, Shandong, China
Linyi Cancer Hospital
🇨🇳Linyi, Shandong, China
Shanxi Cancer Hospital
🇨🇳Datong, Shanxi, China
Sichuan Cancer Hospital
🇨🇳Chengdu, Sichuan, China
The Second Affiliated Hospital of the Chinese People's Liberation Army Air Force Medical University
🇨🇳Xian, Shanxi, China
Tianjin Medical University Cancer Institute and Hospital
🇨🇳Tianjin, Tianjin, China
The First Affiliated Hospital, Zhejiang University School of Medicine
🇨🇳Hangzhou, Zhejiang, China
Zhejiang Cancer Hospital
🇨🇳Hangzhou, Zhejiang, China
Taizhou Hospital of Zhejiang Province
🇨🇳Taizhou, Zhejiang, China
Affiliated Cancer Hospital and Institute of Guangzhou Medical University
🇨🇳Guangzhou, Guangdong, China
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
🇨🇳Guangzhou, Guangdong, China
Related News
MediLink presents YL201 (B7H3 ADC) at ESMO 2024, with over 6-months PFS in SCLC ...
- Prev
- 1
- Next